| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Medical Officer
2 companies
Ozden Rabia Gurses serves as a Chief Medical Officer at OCUL and has filed Form 4s across 2 companies. Across recent SEC filings that breaks down to 0 buys and 4 sells. Those positions are worth an estimated $744K at current prices.
Historically, Ozden Rabia Gurses's trades have earned a below-average insider score of 29/100 across 4 rated trades. Over a 12-month horizon, 0.0% of those trades were profitable, with an average 12-month return of -43.3%.
The biggest single holding is OCUL (~$744K) as Chief Medical Officer. The recent filings there lean toward selling, a net 21,358 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 5, 2024 | OCUL Ocular Therapeutix, Inc | Chief Medical Officer | Sell | 6,346 | $4.86 | $30,841.56 | -4.0% | +17.2% | +58.0% | |
| Jan 31, 2024 | OCUL Ocular Therapeutix, Inc | Chief Medical Officer | Sell | 7,764 | $4.95 | $38,431.80 | -7.7% | -2.5% | +60.1% | |
| Jul 7, 2023 | OCUL Ocular Therapeutix, Inc | Chief Medical Officer | Sell | 832 | $4.93 | $4,101.76 | -0.8% | -39.1% | +36.4% | |
| Feb 6, 2023 | OCUL Ocular Therapeutix, Inc | Chief Medical Officer | Sell | 6,416 | $4.24 | $27,203.84 | -6.0% | +50.6% | +18.6% |